PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy

PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy

Submitted by admin on September 30, 2020 - 11:03pm
Source: 
Pharmaforum
News Tags: 
Vedanta Biosciences
microbiome
C. difficile
BARDA
Headline: 
PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy
snippet: 

US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by a US government agency.


Do Not Allow Advertisers to Use My Personal information